Key result
The AGE cross-link breaker ALT-711 restored LV ejection fraction (which had fallen by 25% due to diabetes), reduced aortic stiffness, and reversed collagen upregulation in aged diabetic dogs.
Why the study?
Does the AGE cross-link breaker phenyl-4,5-dimethylthazolium chloride (ALT-711) improve left ventricular function and reduce myocardial collagen in aging dogs with alloxan-induced diabetes mellitus?
Does the AGE cross-link breaker phenyl-4,5-dimethylthazolium chloride (ALT-711) improve left ventricular function and reduce myocardial collagen in aging dogs with alloxan-induced diabetes mellitus?
The AGE cross-link breaker ALT-711 improves LV function and reduces myocardial collagen and aortic stiffness in an aging diabetic dog model, suggesting potential therapeutic value for aged diabetic patients.
Authors
No takes yet. Share an insight, caveat, or question.
Does not support clinical use in diabetic cardiomyopathy; leaves open translation of ALT-711 benefits to humans.
Liu et al. (2003) studied Aging and diabetes mellitus (n=12). Phenyl-4,5-dimethylthazolium chloride (ALT-711) vs. Untreated diabetic state was evaluated on Myocardial collagen protein content, aortic stiffness, and left ventricular function. The AGE cross-link breaker ALT-711 restored LV ejection fraction (which had fallen by 25% due to diabetes), reduced aortic stiffness, and reversed collagen upregulation in aged diabetic dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: